314 related articles for article (PubMed ID: 30704164)
1. [Value of the detection of
Zhao H; Guo HQ; Zhang ZH; Cao J; Zhao LL; Sun Y; Wang C; Xiao T
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jan; 54(1):18-22. PubMed ID: 30704164
[No Abstract] [Full Text] [Related]
2. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
Wobker SE; Kim LT; Hackman TG; Dodd LG
Cancer Cytopathol; 2015 Sep; 123(9):531-9. PubMed ID: 26080065
[TBL] [Abstract][Full Text] [Related]
3. Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens.
Meng Z; Lu J; Wu H; Zhao Y; Luo Y; Gao J; Zhu Q; Jiang Y; Li W; Liang Z
Tumour Biol; 2016 Jan; 37(1):611-8. PubMed ID: 26240026
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
Dell'Aquila M; Granitto A; Martini M; Capodimonti S; Cocomazzi A; Musarra T; Fiorentino V; Pontecorvi A; Lombardi CP; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
Cancer Cytopathol; 2020 Mar; 128(3):177-189. PubMed ID: 31821747
[TBL] [Abstract][Full Text] [Related]
5. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
[TBL] [Abstract][Full Text] [Related]
6. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
Crescenzi A; Guidobaldi L; Nasrollah N; Taccogna S; Cicciarella Modica DD; Turrini L; Nigri G; Romanelli F; Valabrega S; Giovanella L; Onetti Muda A; Trimboli P
Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
[TBL] [Abstract][Full Text] [Related]
9. The Role of BRAF V600E in Reducing AUS/FLUS Diagnosis in Thyroid Fine Needle Aspiration.
Yin L; Tang Y; Yu S; Wang C; Xiao M; Wang Y; Liu SJ; Gao L; Huang K; Jin L
Endocr Pathol; 2019 Dec; 30(4):312-317. PubMed ID: 31529211
[TBL] [Abstract][Full Text] [Related]
10. The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage.
Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Strupas K
Langenbecks Arch Surg; 2017 Mar; 402(2):227-234. PubMed ID: 28160058
[TBL] [Abstract][Full Text] [Related]
11. VE1 antibody is not highly specific for the BRAF V600E mutation in thyroid cytology categories with the exception of malignant cases.
Lee SR; Yim H; Han JH; Lee KB; Lee J; Soh EY; Kim DJ; Chung YS; Jeong SY; Sheen SS; Park SH; Kim JH
Am J Clin Pathol; 2015 Mar; 143(3):437-44. PubMed ID: 25696803
[TBL] [Abstract][Full Text] [Related]
12. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
Hyeon J; Ahn S; Shin JH; Oh YL
Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
[TBL] [Abstract][Full Text] [Related]
13. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
14. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates.
Marchetti I; Lessi F; Mazzanti CM; Bertacca G; Elisei R; Coscio GD; Pinchera A; Bevilacqua G
Thyroid; 2009 Aug; 19(8):837-42. PubMed ID: 19534623
[TBL] [Abstract][Full Text] [Related]
15. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
16. The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.
Straccia P; Brunelli C; Rossi ED; Lanza P; Martini M; Musarra T; Lombardi CP; Pontecorvi A; Fadda G
Cytopathology; 2019 Sep; 30(5):460-467. PubMed ID: 30875124
[TBL] [Abstract][Full Text] [Related]
17. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
[TBL] [Abstract][Full Text] [Related]
18. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
Rossi ED; Bizzarro T; Martini M; Capodimonti S; Fadda G; Larocca LM; Schmitt F
Cancer Cytopathol; 2014 Dec; 122(12):883-91. PubMed ID: 25156883
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF
Kim JK; Seong CY; Bae IE; Yi JW; Yu HW; Kim SJ; Won JK; Chai YJ; Choi JY; Lee KE
Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028
[TBL] [Abstract][Full Text] [Related]
20. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
Paek SH; Kim BS; Kang KH; Kim HS
World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]